Highlights from ASCO GU 2017 symposium focusing on prostate cancer

1. Prostate Cancer
“Highlights from ASCO GU – 2017”
Mohamed Abdulla M.D.
Prof. of Clinical Oncology
Cairo University
Astellas Astellas Symposium
02/04/2017
Grand Nile Tower

2. Member of Advisory Board, Consultant, and Speaker for:
• Amgen, Astellas, AstraZeneca, Hoffman la Roche, Janssen Cilag,
Merck Serono, Novartis, Pfizer, Mundipharma, MSD
Speaker Disclosures:

3. Outline:
1. Disease demographics and screening.

4. Demographics of Prostate Cancer:
Metastatic Disease at Presentation:
Gilbert Welch et al. NEGM. 2015;373:1685-1687
50%

5. Demographics of Prostate Cancer:
Changes in Mortality Rates:
Kelly et al. EUROPEAN UROLOGY 71 (2017) 195–201

6. Demographic: Context

7. Demographic: Metastases

8. Demographics & USPSTF

9. Demographics & USPSTF

10. Screening: PLCO

11. Outline:
1. Disease demographics and screening.
2. Pathology – Classification.

12. Pathology - Classification

13. Pathology - Classification

14. Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.

15. Localized disease - Treatment

16. Localized disease - Treatment

17. Localized disease - Treatment

18. Localized disease - Treatment

19. Localized disease - Treatment

20. Localized disease – Secondary Ca

21. Localized disease - Surgery

22. Localized disease - Surgery

23. Localized disease - Surgery

24. Localized disease - Surgery

25. Localized disease - Radiation

26. Localized disease - Radiation

27. Localized disease - Radiation

28. Salvage Radiotherapy: GETUG-AFU 16

29. Salvage Radiotherapy: GETUG-AFU 16

30. Salvage Radiotherapy: RTOG 9601

31. Salvage Radiotherapy: RTOG 9601

32. Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.

33. Metastatic disease: Stampede

34. Metastatic disease: Stampede

35. Metastatic disease: Stampede

36. Metastatic disease: Docetaxol

37. Metastatic disease: Docetaxol

38. Metastatic disease: TERRAIN RCT

39. Metastatic disease: STRIVE RCT

40. Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.
5. DNA Repair Genes.

41. Slide 75

42. TOPARP Phase 2 Trial:
Mateo etl. N Engl J Med.2015:373;18.

43. DNA Repair & Metastatic PCa

44. DNA Repair & Metastatic PCa

45. Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.
5. DNA Repair Genes.
6. Intrinsic Subtypes of Prostate Cancer.

46. Introduction

47. PAM50 clustering readily identifies luminal (A & B) and basal subtypes in prostate cancer

48. Luminal B prostate cancers have worse outcomes compared to Luminal A or Basal subtypes

49. Multivariable analysis for metastatic progression

50. Different biological pathways are up- or down-regulated in luminal versus basal subtypes<br />

51. Does subtype predict response to ADT?

52. Which patients should receive androgen deprivation early in the course of recurrence?

53. Which patients should receive androgen deprivation early in the course of recurrence?

54. Not all patients benefit from the addition of anti-androgen therapy to salvage radiotherapy

55. The next step: Molecular stratification

56. Conclusions

57. Thank You